EP1462106A1 — Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders

USPTO Abstract

The present invention is concerned with a method of treating or preventing an estrogen sensitive gynaecological disorder in a female mammal, said method comprising administering to the female a combination of estrogen and progestogen continuously for at least 3 months, wherein the estrogen is selected from the group consisting of 17β-estradiol, precursors of 17β-estradiol and combinations thereof, said estrogen being administered in an amount equivalent to a daily oral dosage of 2.2-5 mg 17β-estradiol and said progestogen being administered in an amount equivalent to a daily oral dose of 5-50 mg dydrogesterone. Another aspect of the invention relates to a kit comprising a plurality of oral dosage units, said plurality of daily hormone units containing an estrogen in an amount equivalent to 2.2-5 mg 17β-estradiol and a progestogen in an amount equivalent to 5-50 mg dydrogesterone, wherein the estrogen is selected from the group consisting of 17β-estradiol, precursors of 17β-estradiol and combinations thereof.